


COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS

(Amendments are illustrated by showing deletions by ~~striking through~~ or [[double brackets]] and additions by underlining)

1 (currently amended): A compound of formula I,



wherein

```
n1 is 1;
```


X is, independently for each occurrence, $(\text{CHR}^{11})_{n3}(\text{CH}_2)_{n4}\text{Z}(\text{CH}_2)_{n5};$

Z is 0, $N(R^{12})$, S, or a bond;

n3 is, independently for each occurrence, 0 or 1;

n4 and n5 each is, independently for each occurrence,
0, 1, 2, or 3;

Y is, independently for each occurrence, CO, CH₂, CS, or a bond:



R², R¹¹, and R¹² each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl and

aryl, wherein said optionally substituted moiety is optionally substituted with one or more of R^8 or R^{30} ; R^3 is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C_{1-6}) alkyl, (C_{2-6}) alkenyl, (C_{2-6}) alkynyl, (C_{3-6}) cycloalkyl, (C_{3-6}) cycloalkyl (C_{1-6}) alkyl, (C_{5-7}) cycloalkenyl, (C_{5-7}) cycloalkenyl (C_{1-6}) alkyl, aryl, aryl (C_{1-6}) alkyl, heterocyclyl, and heterocyclyl (C_{1-6}) alkyl, wherein said optionally substituted moiety is optionally substituted with one or more R^{30} ;

R^4 and R^5 each is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C_{1-6}) alkyl, (C_{3-6}) cycloalkyl, aryl, and heterocyclyl, wherein said optionally substituted moiety is optionally substituted with one or more R^{30} , wherein each said substituent is independently selected, or R^4 and R^5 can be taken together with the carbons to which they are attached to form aryl;

R^6 is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C_{1-6}) alkyl, (C_{2-6}) alkenyl, (C_{3-6}) cycloalkyl, (C_{3-6}) cycloalkyl (C_{1-6}) alkyl, (C_{5-7}) cycloalkenyl, (C_{5-7}) cycloalkenyl (C_{1-6}) alkyl, aryl, aryl (C_{1-6}) alkyl, heterocyclyl, and heterocyclyl (C_{1-6}) alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of OH, (C_{1-6}) alkyl, (C_{1-6}) alkoxy, $N(R^8R^9)$, $COOH$, $CON(R^8R^9)$, and halo X^1 , X^2 , and X^3 ,

where R^8 and R^9 each is, independently for each occurrence, H, (C_{1-6}) alkyl, (C_{2-6}) alkenyl, (C_{2-6}) alkynyl, aryl, or aryl (C_{1-6}) alkyl;


R^7 is, independently for each occurrence, H, =O, =S, or an optionally substituted moiety selected from the group consisting of (C_{1-6}) alkyl, (C_{2-6}) alkenyl, (C_{3-6}) cycloalkyl,

~~(C₃₋₆)cycloalkyl(C₁₋₆)alkyl, (C₃₋₇)cycloalkenyl,~~
~~(C₅₋₇)cycloalkenyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl,~~
~~heterocyclyl, and heterocyclyl(C₁₋₆)alkyl, wherein said~~
~~optionally substituted moiety is optionally substituted with~~
~~one or more substituents each independently selected from~~
~~the group consisting of OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, N(R⁸R⁹),~~
~~-COOH, -CON(R⁸R⁹), and halo X¹, X², and X³;~~

R¹⁰ is C;

R²¹ is, independently for each occurrence, H or an optionally substituted moiety selected from the group consisting of (C₁₋₆)alkyl and aryl(C₁₋₆)alkyl, wherein said optionally substituted moiety is optionally substituted with one or more substituents each independently selected from the group consisting of R⁸ and R³⁰;

R²² is H, (C₁₋₆)alkylthio, (C₃₋₆)cycloalkylthio, R⁸-CO-, or a substituent according to the formula



R²⁴ and R²⁵ each is, independently for each occurrence, H, (C₁₋₆)alkyl, or aryl(C₁₋₆)alkyl;


R³⁰ is, independently for each occurrence, (C₁₋₆)alkyl, -O-R⁸, -S(O)_{n6}R⁸, -S(O)_{n7}N(R⁸R⁹), -N(R⁸R⁹), -CN, -NO₂;

$-\text{CO}_2\text{R}^8$, $-\text{CON}(\text{R}^8\text{R}^9)$, ~~$-\text{NCO}-\text{R}^8$~~ $-\text{NH}-\text{CO}-\text{R}^8$, or halogen;


n_6 and n_7 each is, independently for each occurrence, 0, 1, or 2;
 wherein said heterocyclyl is azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazolynyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, or thienyl; and wherein said aryl is phenyl or naphthyl;

provided that:

either R^6 is H or R^7 is $=\text{O}$, $-\text{H}$, or $=\text{S}$ wherein when R^6 is H,




then R^{10} and R^7 are taken together to form (R^{10}) ; or when R^7 is $=\text{O}$, $-\text{H}$, or $=\text{S}$, then R^{10} and R^6 are taken together



to form


wherein X^1 , X^2 , and X^3 each is, independently, H, halogen, $-\text{NO}_2$, $-\text{NCO}-\text{R}^8$, $-\text{NH}-\text{CO}-\text{R}^8$, $-\text{CO}_2\text{R}^8$, $-\text{CN}$, or $-\text{CON}(\text{R}^8\text{R}^9)$; and

~~when R^1 is $\text{N}(\text{R}^{24}\text{R}^{25})$, then n_3 is 1, n_4 and n_5 each is 0, Z is a bond, and R^3 and R^{11} can be taken together to form~~



~~wherein n_2 is 1-6, and X^4 and X^5 each is, independently, H, (C_{1-6}) alkyl, or aryl, or X^4 and X^5 can be taken together to form (C_{3-6}) cycloalkyl,~~
 or a pharmaceutically acceptable salt thereof.


2 (original): A compound according to claim 1, wherein:



$\text{N}(\text{R}^{24}\text{R}^{25})$; and

X is $\text{CH}(\text{R}^{11})_{n_3}(\text{CH}_2)_{n_4}$ or Z , wherein Z is O, S, or $\text{N}(\text{R}^{12})$; or a pharmaceutically acceptable salt thereof.

3 (withdrawn): A compound according to claim 2, wherein:




X is $\text{CH}(\text{R}^{11})_{n_3}(\text{CH}_2)_{n_4}$; and

n1 is 0;

or a pharmaceutically acceptable salt thereof.

4 (withdrawn): A compound according to claim 2,
 wherein:



R¹ is R²²-S ;

n3, n4, and n5 each is 0;


Z is a bond;

Y is, independently for each occurrence, CO or CS; and

n1 is 0;

or a pharmaceutically acceptable salt thereof.


5 (original): A compound according to claim 2,
 wherein:



R¹ is ;

R⁶ is H;

n1 is 1;



R⁷ and R¹⁰ are taken together to form

n3 is 1 and R¹¹ is H;

Z is O or a bond;

n5 is 0; and

Y is CO, CH₂, or a bond;

or a pharmaceutically acceptable salt thereof.

6 (withdrawn): A compound according to claim 2,
 wherein:

R^1 is $N(R^{24}R^{25})$;

$n1$ is 0;


$n3$ is 1;

$n4$ is 0;

$n5$ is 0;


Y is CO or CS;

Z is a bond; and



R^3 and R^{11} are taken together to form
 or a pharmaceutically acceptable salt thereof.


7 (original): A compound according to claim 2,
 wherein:



R^1 is ;

R^7 is H or =O;

$n1$ is 1;



R^6 and R^{10} are taken together to form

$n3$ is 1 and R^{11} is H;

$n5$ is 0;

Y is CO or CH_2 ; and

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 9

Z is O or a bond;

or a pharmaceutically acceptable salt thereof.

8 (withdrawn): A compound according to claim 3,
wherein said compound is

8-butyl-7-(3-(imidazol-5-yl)-1-oxopropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

8-butyl-2-(2-hydroxyphenyl)-7-(imidazol-4-yl-propyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

8-butyl-7-(4-imidazolylpropyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(imidazol-4-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(1-oxo-2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

2-(2-methoxyphenyl)-8-(1-methylpropyl)-7-(2-(1-phenylmethyl)-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-((1H-imidazol-4-yl)methyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-((4-imidazolyl)carbonyl)-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(1-(4-cyanophenylmethyl)-imidazol-5-yl)methyl-2-(2-methoxyphenyl)-8-(1-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

5-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 10

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

6-butyl-7-(2-(4-cyanophenylmethylimidazol-5-yl)-1-oxo-ethyl)-2-phenyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;

5-butyl-7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(1-(4-cyanophenylmethyl)-imidazole-5-yl)-1-oxo-ethyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

5-butyl-7-(2-(1H-imidazole-5-yl)-1-oxo-ethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine;

7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-2-(2-(phenylmethoxy)-phenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine; or

2-(2-butoxyphenyl)-7-(2-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxo-ethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine;
or a pharmaceutically acceptable salt thereof.

9 (previously presented): A compound according to claim 5, wherein said compound is

1,2-dihydro-1-((1H-imidazol-4-yl)methyl)-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine ;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

or a pharmaceutically acceptable salt thereof.

10 (previously presented): A compound according to claim 9, wherein said compound is

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

9-chloro-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

10-bromo-1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine; or

1-(2-(1-(4-cyanophenylmethyl)imidazol-4-yl)-1-oxoethyl)-1,2-dihydro-8-fluoro-4-(2-methoxyphenyl)-imidazo[1,2-c][1,4]benzodiazepine;

or a pharmaceutically acceptable salt thereof.

11 (withdrawn): A compound according to claim 6, wherein said compound is

7-(2-amino-1-oxo-3-thiopropyl)-8-(mercaptoethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine disulfide;

or a pharmaceutically acceptable salt thereof.

12 (original): A compound according to claim 7, wherein said compound is

5-(2-(1-(4-cyanophenylmethyl)-imidazol-5-yl)-1-oxoethyl)-5,6-dihydro-2-phenyl-1H-imidazo[1,2-a][1,4]benzodiazepine;
or a pharmaceutically acceptable salt thereof.


13 (currently amended): A compound according to claim 2 wherein said compound is

1,2-dihydro-1-(2-(imidazol-1-yl)-1-oxoethyl)-4-(2-methoxyphenyl) imidazo[1,2-a][1,2-a][1,4]benzodiazepine;







1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-3-yl)-1-oxoethyl) imidazo[1,2-a][1,2-a][1,4]benzodiazepine; or


1,2-dihydro-4-(2-methoxyphenyl)-1-(2-(pyridin-4-yl)-1-oxoethyl) imidazo[1,2-a][1,2-a][1,4]benzodiazepine;
or a pharmaceutically acceptable salt thereof.

14 (previously presented): A compound according to claim 2, wherein said compound is



Inventor :
Serial No. :
Filed :
Page :





or a pharmaceutically acceptable salt thereof.

15 (currently amended): A pharmaceutical composition for ~~use in treating a disease selected from the group consisting~~ the treatment of breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer, epidermal cancer, ~~and~~ or hematopoietic cancer, in a patient in need thereof, comprising ~~an~~ a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein said therapeutically effective amount is an amount that is effective for the treatment of breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer, epidermal cancer, or hematopoietic cancer in said patient.





16 (previously presented): A method of treating a disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said






disease is selected from the group consisting of breast cancer, colon cancer, pancreas cancer, prostate cancer, lung cancer, ovarian cancer, epidermal cancer and hematopoietic cancer.

17 (canceled)


18 (canceled)

19 (original): A compound according to claim 2, wherein said compound is





; or



or a pharmaceutically acceptable salt thereof.

20 (currently amended): A pharmaceutical composition for ~~use in treating a disease selected from the group consisting~~ the treatment of fibrosis, benign prostatic hyperplasia, atherosclerosis, restenosis ~~and~~ or hepatitis delta virus infection in a patient in need thereof, comprising ~~an~~ a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein said therapeutically effective amount is an amount that is effective for the treatment of fibrosis, benign prostatic hyperplasia, atherosclerosis, restenosis or hepatitis delta virus infection in said patient.

21 (previously presented): A method of treating a disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said disease is selected from the group consisting of fibrosis,

Inventor : Gordon et al.
Serial No. : 09/868,356
Filed : August 10, 2001
Page : 18

benign prostatic hyperplasia, atherosclerosis, restenosis and
hepatitis delta virus infection.